Literature DB >> 9850872

Natural history of Alzheimer's disease and other dementias: review of the literature in the light of the findings from the Kungsholmen Project.

H Agüero-Torres1, L Fratiglioni, B Winblad.   

Abstract

The elderly population is increasing more than any other sector of the population. Dementia, a prevalent condition in the elderly, increases disability, morbidity and mortality among older people. For these reasons the possibility of predicting progression and prognosis has enormous importance. Despite the fact that dementia has gained widespread recognition in the past few decades, the knowledge of its natural history, in terms of progression and prognosis are not yet completely understood. However, thanks to longitudinal research, which has only recently begun to proliferate, not only is better comprehension of the continuity of the cognitive decline possible, but also the identification of some prognostic factors.

Entities:  

Mesh:

Year:  1998        PMID: 9850872     DOI: 10.1002/(sici)1099-1166(1998110)13:11<755::aid-gps862>3.0.co;2-y

Source DB:  PubMed          Journal:  Int J Geriatr Psychiatry        ISSN: 0885-6230            Impact factor:   3.485


  24 in total

1.  Latent classes of course in Alzheimer's disease and predictors: the Cache County Dementia Progression Study.

Authors:  Jeannie-Marie S Leoutsakos; Sarah N Forrester; Christopher D Corcoran; Maria C Norton; Peter V Rabins; Martin I Steinberg; Joann T Tschanz; Constantine G Lyketsos
Journal:  Int J Geriatr Psychiatry       Date:  2014-11-03       Impact factor: 3.485

2.  Effects of general medical health on Alzheimer's progression: the Cache County Dementia Progression Study.

Authors:  Jeannie-Marie S Leoutsakos; Dingfen Han; Michelle M Mielke; Sarah N Forrester; JoAnn T Tschanz; Chris D Corcoran; Robert C Green; Maria C Norton; Kathleen A Welsh-Bohmer; Constantine G Lyketsos
Journal:  Int Psychogeriatr       Date:  2012-06-12       Impact factor: 3.878

3.  Progression of cognitive, functional, and neuropsychiatric symptom domains in a population cohort with Alzheimer dementia: the Cache County Dementia Progression study.

Authors:  JoAnn T Tschanz; Chris D Corcoran; Sarah Schwartz; Katherine Treiber; Robert C Green; Maria C Norton; Michelle M Mielke; Kathleen Piercy; Martin Steinberg; Peter V Rabins; Jeanne-Marie Leoutsakos; Kathleen A Welsh-Bohmer; John C S Breitner; Constantine G Lyketsos
Journal:  Am J Geriatr Psychiatry       Date:  2011-06       Impact factor: 4.105

4.  [Alzheimer's disease].

Authors:  U Yilmaz
Journal:  Radiologe       Date:  2015-05       Impact factor: 0.635

5.  "Dementia-friendly hospitals: care not crisis": an educational program designed to improve the care of the hospitalized patient with dementia.

Authors:  James E Galvin; Barbara Kuntemeier; Noor Al-Hammadi; Jessica Germino; Maggie Murphy-White; Janis McGillick
Journal:  Alzheimer Dis Assoc Disord       Date:  2010 Oct-Dec       Impact factor: 2.703

6.  Data requirements in a model of the natural history of Alzheimer's disease.

Authors:  T J Chaussalet; W A Thompson
Journal:  Health Care Manag Sci       Date:  2001-02

7.  The Cache County Study on Memory in Aging: factors affecting risk of Alzheimer's disease and its progression after onset.

Authors:  Joann T Tschanz; Maria C Norton; Peter P Zandi; Constantine G Lyketsos
Journal:  Int Rev Psychiatry       Date:  2013-12

Review 8.  Memantine: a pharmacoeconomic review of its use in moderate-to-severe Alzheimer's disease.

Authors:  Greg L Plosker; Katherine A Lyseng-Williamson
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

9.  Assessment of Health Economics in Alzheimer's Disease (AHEAD): treatment with galantamine in Sweden.

Authors:  Frances B Garfield; Denis Getsios; J Jaime Caro; Anders Wimo; Bengt Winblad
Journal:  Pharmacoeconomics       Date:  2002       Impact factor: 4.981

Review 10.  Assessing and predicting functional impairment in Alzheimer's disease: the emerging role of frontal system dysfunction.

Authors:  Patricia A Boyle
Journal:  Curr Psychiatry Rep       Date:  2004-02       Impact factor: 5.285

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.